FIGURE 4.

Pharmacokinetics of levosimendan: A, Differences in the area under the receiver operating characteristics curve (AUC) for changes in Doppler echocardiography–derived PCWP and CO in patients with acute HF treated with levosimendan or placebo (n = 11 in both groups) for 24 hours. Due to of the formation of the active metabolite, the hemodynamic effects are maintained several days after stopping levosimendan infusion. B, Median change in N-terminal prohormone atrial natriuretic peptide (NT-proANP) over 14 days in patients with HF receiving levosimendan or placebo (n = 11 in both groups) for 24 hours. Source: Lilleberg et al⁵⁸ Reproduced with permission from John Wiley and Sons.